Draft:Genfit
 | This article may have been created or edited in return for undisclosed payments, a violation of Wikipedia's terms of use. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. |
| Company type | Public company |
|---|---|
| Euronext: GNFT NASDAQ (GNFT) | |
| Founded | 1999 |
| Headquarters | |
Key people | Jean-François Mouney (Chairman) and Pascal Prigent (CEO) |
| Revenue | €0.7 million (2020) ; €31 million (2019) |
| -€65 million (2019 losses) | |
Number of employees | 175 (2019) |
| Website | genfit.com |
Genfit is a French biotechnology company.[1] It's research and clinical trials in the fields of cardiovascular disease and liver disease, especially of metabolic origin.[2] Genfit is also involved in the development of medical diagnostic technology. [3]
It has been listed on the Euronext Paris stock exchange since 2006[4] and on the NASDAQ since 2019.[5]
History and Activity
Genfit was founded in 1999 in Lille by Jean-François Mouney and Florence Séjourné with the support of professors Bart Staels and Jean-Charles Fruchart.[6][7] The company initially focused on the development of drugs for cardiovascular diseases and obesity. In 2006, Genfit went public on Alternext, raising €15 million.[4] In 2014, the company's stock was included in the SBF 120 index.[8] However, it was removed from the index in 2020.[9]
In 2016, Genfit raised €44.6 million in a capital increase.[10][11] In 2017, the company issued €180 million of convertible bonds (OCEANE) to institutional investors.[12] Half of the amount of these bonds was cancelled in January 2021 and the balance carried forward to the end of 2025.[13]
In March 2019, Genfit also listed on the Nasdaq, raising $135.1 million.[5] In September 2019, CEO Jean-François Mouney became Chairman of the Board of Directors and Pascal Prigent became CEO.[6]
In May 2020, Genfit discontinued its "investigations into the treatment of non-alcoholic steatohepatitis (NASH)".[14] As of late September 2020, the company is focusing on "primary biliary cholangitis (PBC) and NIS4, a blood diagnostic technology that, if approved, would identify patients at risk of NASH".[14]
References
- ^ Vermot, Thibault. "Vaccins : les laboratoires veulent faire la Bourse en tête". Libération (in français). Retrieved 2024-04-23.
- ^ "Profil société Genfit, activité, actionnaires et dirigeants de l'entreprise GNFT - FR0004163111 - Boursier.com". www.boursier.com. Retrieved 2024-04-23.
- ^ "Genfit : La biotech Genfit va commercialiser aux Etats-Unis son outil de diagnostic de la NASH". BFM Bourse (in français). 2020-09-28. Retrieved 2024-04-23.
- ^ 4.0 4.1 "Les biotech retrouvent la cote". L'Express (in français). 2007-01-24. Retrieved 2024-04-23.
- ^ 5.0 5.1 "La biotech française Genfit fait son entrée au Nasdaq". Le Figaro (in français). 2019-03-27. Retrieved 2024-04-23.
- ^ 6.0 6.1 "Genfit : Jean-François Mouney cède la direction générale de Genfit à Pascal Prigent". BFM Bourse (in français). 2019-09-02. Retrieved 2024-04-23.
- ^ "Genfit - Document d'Enregistrement Universel 2019". ir.genfit.com. 2020-05-20. Retrieved 2024-04-23.
- ^ "Valeo remplace Vallourec dans le CAC 40". Les Echos (in français). 2014-06-05. Retrieved 2024-04-23.
- ^ "Genfit : Exclusion du SBF 120 et du CAC Mid 60". BFM Bourse (in français). 2020-12-11. Retrieved 2024-04-23.
- ^ "Genfit : lève 44,6 millions d'euros lors de son augmentation de capital - Zonebourse". www.zonebourse.com (in français). 2016-10-31. Retrieved 2024-04-23.
- ^ "Genfit : Augmentation de capital de 44,6 millions d'euros". BFM Bourse (in français). 2016-10-10. Retrieved 2024-04-23.
- ^ "GENFIT réalise l'émission d'OCEANE pour 180 millions d'euros - Capital.fr". capital.fr. 2017-10-17. Archived from the original on 2020-11-28. Retrieved 2024-04-23.
- ^ "Genfit va pouvoir effacer près de 50% de sa dette obligataire". Boursier.com (in français). 2021-01-25. Retrieved 2024-04-23.
- ^ 14.0 14.1 "Flambée pour Genfit après des résultats positifs - Boursorama". boursorama.com. 2021-02-10. Archived from the original on 2021-02-10. Retrieved 2024-04-23.
External links
Lua error in mw.title.lua at line 346: bad argument #2 to 'title.new' (unrecognized namespace name 'Portal').
Category:Companies listed on Euronext Paris Category:Biotechnology companies of France Category:Companies established in 1999 Category:Companies listed on Nasdaq exchanges